The news: Eli Lilly reported weaker-than-expected sales in Q3 for its two GLP-1 blockbuster medications, Mounjaro and Zepbound.
- For Q3 2024, worldwide Mounjaro revenues were $3.11 billion, while Zepbound brought in $1.26 billion in the US.
- Analysts expected Mounjaro sales at $4.2 billion and $1.69 billion for Zepbound, according to LSEG data cited by Reuters.
- Zepbound sales slightly decreased quarter over quarter, while sales for Mounjaro slightly increased.